Foresite Capital Management Vi LLC Corvus Pharmaceuticals, Inc. Transaction History
Foresite Capital Management Vi LLC
- $178 Billion
- Q2 2025
A detailed history of Foresite Capital Management Vi LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Foresite Capital Management Vi LLC holds 1,731,233 shares of CRVS stock, worth $7.79 Million. This represents 3.89% of its overall portfolio holdings.
Number of Shares
1,731,233
Previous 1,581,233
9.49%
Holding current value
$7.79 Million
Previous $5.03 Billion
37.72%
% of portfolio
3.89%
Previous 2.75%
Shares
2 transactions
Others Institutions Holding CRVS
# of Institutions
112Shares Held
39.6MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$31.2 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$18.3 Million0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$14.8 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$14.7 Million9.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$12.5 Million0.02% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $209M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...